Abstract Body

Breastfeeding is a critical child survival strategy. Its importance for child health and survival beyond HIV has stood the test of rigorous research, even in high HIV prevalence settings. However, infants can acquire HIV infection through infected breastmilk. Following the implementation of Option B+ (lifelong triple antiretroviral therapy (ART) for pregnant and lactating women) to prevent mother to child HIV transmission, multiparous mothers are likely to conceive on ART, pregnant women are likely to initiate ART earlier in pregnancy and breastfeeding mothers should initiate ART during lactation. This earlier and increased antiretroviral use provides a platform for maternal HIV viral load suppression and for eliminating mother to child HIV transmission as a public health problem (MTCT). Eliminating MTCT is defined as less than five percent MTCT and ≤50 new paediatric HIV infections per 100 000 live births. This talk will synthesize current data and field-based experiences on the epidemiology, timing, virology and risk of breast milk HIV transmission including risks for mothers on ART, the role of post-exposure infant prophylaxis, the interplay between breastmilk intake and viral load suppression and dilemmas for resource poor settings, to answer the question: Can we eliminate breastmilk transmission of HIV? Data from Africa, where infectious diseases are the main contributors to infant and under-five morbidity and mortality, and breastfeeding is a key child survival strategy, suggest that maternal ART adherence is sub-optimal, few mothers receive regular viral load monitoring and where viral suppression is known, 16-78% of people living with HIV are virally suppressed. This questions the feasibility of eliminating breastmilk MTCT in real-life resource-limited settings. Additionally, the percent MTCT yielded by different clinical trials of mothers on ART, ranges from 1.1% at 6 months to 0.6% at 12 months, and 1.4% at 18 months. Using clinic/facility-level data, MTCT percentages of 3.5% at 6-12 weeks, 4.1% at 18 months and 3.2% at 24 months have been described. With 4.1% MTCT, the EMTCT target will only be achieved if maternal HIV prevalence is <0.12%. This massive decline in maternal HIV prevalence is unlikely; thus combination strategies of maternal ART with support for ART adherence and maternal and / or infant passive or active vaccination may be the next holy grail.